Kelei Limited Submits Second Listing Application to Hong Kong Stock Exchange

According to Hong Kong Stock Exchange disclosure on June 30, Kelei Limited submitted a listing application to the HKEx main board, with China International Capital Corporation as the sole sponsor. The company previously submitted an application on December 18, 2025. By 2025 revenue, Kelei ranked in the top ten of China's pharmaceutical marketing, promotion, and sales market with approximately 2.0% market share, and was the country's largest pediatric pharmaceutical services provider with around 17.0% market share.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments